Vir Biotechnology stock gains on new 52-week high and conference appearance
Published on 09/03/2026 at 08:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vir Biotechnology stock (ISIN US92764N1028) has recently reached a new 52-week high, underlining the strong momentum in the biotech group ahead of its appearance at a major healthcare investor conference in early September 2026.
Stock touches a new 52-week high
According to data compiled by MarketBeat, Vir Biotechnology shares recently set a new 52-week high at USD 11.74, compared with the prior closing level of USD 10.94.
The same overview notes that the stock closed at USD 11.63 as of September 1, 2026, which represents an increase of 6.31% on the day and places the price near the top end of its trading range over the past year.
Analyst sentiment and price targets
Analyst sentiment toward Vir Biotechnology is described as generally positive, with a consensus rating of Moderate Buy and an average price target of USD 21.57, according to the analyst and ownership summary presented by MarketBeat.
In the same note, Leerink Partners is reported to have raised its price target for Vir Biotechnology shares from USD 20.00 to USD 21.00 and maintained an Outperform rating, highlighting expectations for further upside potential relative to the share price of USD 11.63 reported as of September 1, 2026.
MarketBeat also points out that, since a prior low earlier in the year, Vir Biotechnology stock has gained 92.9% and is now trading at USD 11.63 as of September 1, 2026, illustrating a substantial recovery in investor confidence over recent months.
Conference participation as near-term catalyst
A potential near-term catalyst for Vir Biotechnology stock is its planned participation in the Morgan Stanley 24th Annual Global Healthcare Conference, as highlighted by a news-based gainers overview on StockTitan.
This overview notes that Vir Biotechnology shares rose 6.31% on September 1, 2026, against the close of August 31, 2026, and associates the move with an announcement that the company will participate in the Morgan Stanley conference, indicating that investors are positioning ahead of potential new information on strategy, pipeline progress or financial guidance.
StockTitan estimates Vir Biotechnology’s market capitalization at around USD 1.97 billion as of early September 2026, a level that reflects the strong share price recovery and provides a scale reference within the biotechnology sector.
Representative product focus: infectious disease therapies
Vir Biotechnology is positioned as a biotechnology company focused on developing therapies for serious infectious diseases, including viral infections that remain a significant global health burden.
For investors, the current focus lies on how successfully Vir Biotechnology can turn its scientific platform into sustainable revenues and profits over the coming quarters, particularly in areas where antiviral therapies or monoclonal antibodies may address unmet medical needs.
Stock level and investor perspective
Based on the MarketBeat stock analysis page for Vir Biotechnology, the shares closed at USD 11.63 on Nasdaq on September 1, 2026, up 6.31% on the day, and close to the freshly marked 52-week high of USD 11.74, underscoring the positive sentiment heading into the Morgan Stanley conference.
Vir Biotechnology stock snapshot
- Company: Vir Biotechnology Inc.
- ISIN: US92764N1028
- Ticker: VIR
- Trading venue: Nasdaq
- Price (as of September 1, 2026): 11.63 USD
- Market capitalization: 1.97 billion USD (as of September 1, 2026)
- Sector / Industry: Biotechnology
- Index membership: Nasdaq biotechnology universe
